Overview

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborators:

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Medivation, Inc.

Treatments:

Androgens
Trastuzumab